BGM
BGM
BGM Group Ltd.Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $14.31M ▲ | $4.31M ▲ | $-861.22K ▼ | -6.02% ▼ | $-0.01 ▼ | $-1.8M ▼ |
| Q2-2024 | $12.56M | $2.09M | $328.78K | 2.62% | $0.05 | $-679.09K |
What's going well?
Sales are up 14% and gross profit is rising even faster, showing strong demand. Gross margins improved, suggesting better pricing or cost control.
What's concerning?
Operating expenses have exploded, far outpacing revenue growth, and the company is now losing money. Shareholders are diluted, and the business is less efficient and unprofitable.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $14.54M ▼ | $207.39M ▲ | $23.9M ▲ | $182.12M ▲ |
| Q4-2024 | $18.14M ▼ | $53M ▲ | $8.91M ▲ | $42.74M ▼ |
| Q2-2024 | $25.36M ▲ | $49.85M ▼ | $4.93M ▼ | $43.43M ▲ |
| Q4-2023 | $22.42M ▲ | $51.26M ▼ | $6.91M ▼ | $42.79M ▼ |
| Q2-2023 | $8.88M | $64.23M | $9.5M | $52.85M |
What's financially strong about this company?
BGM has a huge equity cushion, very low debt, and plenty of liquid assets to pay its bills. The company can easily weather short-term challenges and has flexibility for future growth.
What are the financial risks or weaknesses?
The balance sheet is now heavily weighted toward goodwill, which could be written down if acquisitions disappoint. Receivables and inventory are rising fast, which could tie up cash or signal slower customer payments.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-430.61K | $-3.06M | $-3.26M | $7.36M | $-165.53K | $-4.07M |
What's strong about this company's cash flow?
The company still has $9.65 million in cash, and was able to raise funds through both debt and equity. If operations improve, they have some breathing room to turn things around.
What are the cash flow concerns?
BGM is burning cash quickly, with negative operating and free cash flow. The company is highly dependent on outside funding, and working capital is getting worse, not better.
5-Year Trend Analysis
A comprehensive look at BGM Group Ltd.'s financial evolution and strategic trajectory over the past five years.
BGM’s main strengths are its strong, debt‑free balance sheet, solid liquidity, and willingness to invest in innovation despite short‑term pressure. The company has a legacy base of technical know‑how in pharmaceuticals and traditional medicine, and it has acquired AI platforms and capabilities that, if integrated well, could position it in attractive parts of the insurance and healthcare value chain. Recent improvements in gross margins and cost control show that management is actively adjusting the business rather than remaining static.
Key risks include the sharp and ongoing decline in revenue, persistent accounting and cash losses, and highly volatile cash flows. The strategic pivot is complex: combining pharma, healthcare, and insurance AI requires integrating very different businesses and managing regulatory, operational, and cultural challenges. Competitive intensity is high in both core areas – generic pharma and AI‑driven financial services – leaving limited room for missteps. Continued negative free cash flow could, over time, erode the current cash cushion and force the company to consider new financing or further restructuring if profitability does not recover.
The outlook for BGM is best described as uncertain and execution‑dependent. The balance sheet gives the company time to pursue its transformation, but the income statement and cash flows indicate that the traditional business alone is unlikely to restore past profitability. Future performance will hinge on stabilizing the legacy pharma segment, successfully scaling the AI insurance platforms, and translating rising R&D and capital investment into durable, cash‑generating revenue streams. Until there is clearer evidence of sustained top‑line growth and positive free cash flow from the new strategy, results are likely to remain volatile and sensitive to both market and execution factors.
About BGM Group Ltd.
https://www.bgm.ltdBGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q2-2025 | $14.31M ▲ | $4.31M ▲ | $-861.22K ▼ | -6.02% ▼ | $-0.01 ▼ | $-1.8M ▼ |
| Q2-2024 | $12.56M | $2.09M | $328.78K | 2.62% | $0.05 | $-679.09K |
What's going well?
Sales are up 14% and gross profit is rising even faster, showing strong demand. Gross margins improved, suggesting better pricing or cost control.
What's concerning?
Operating expenses have exploded, far outpacing revenue growth, and the company is now losing money. Shareholders are diluted, and the business is less efficient and unprofitable.
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q2-2025 | $14.54M ▼ | $207.39M ▲ | $23.9M ▲ | $182.12M ▲ |
| Q4-2024 | $18.14M ▼ | $53M ▲ | $8.91M ▲ | $42.74M ▼ |
| Q2-2024 | $25.36M ▲ | $49.85M ▼ | $4.93M ▼ | $43.43M ▲ |
| Q4-2023 | $22.42M ▲ | $51.26M ▼ | $6.91M ▼ | $42.79M ▼ |
| Q2-2023 | $8.88M | $64.23M | $9.5M | $52.85M |
What's financially strong about this company?
BGM has a huge equity cushion, very low debt, and plenty of liquid assets to pay its bills. The company can easily weather short-term challenges and has flexibility for future growth.
What are the financial risks or weaknesses?
The balance sheet is now heavily weighted toward goodwill, which could be written down if acquisitions disappoint. Receivables and inventory are rising fast, which could tie up cash or signal slower customer payments.
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q2-2025 | $-430.61K | $-3.06M | $-3.26M | $7.36M | $-165.53K | $-4.07M |
What's strong about this company's cash flow?
The company still has $9.65 million in cash, and was able to raise funds through both debt and equity. If operations improve, they have some breathing room to turn things around.
What are the cash flow concerns?
BGM is burning cash quickly, with negative operating and free cash flow. The company is highly dependent on outside funding, and working capital is getting worse, not better.
5-Year Trend Analysis
A comprehensive look at BGM Group Ltd.'s financial evolution and strategic trajectory over the past five years.
BGM’s main strengths are its strong, debt‑free balance sheet, solid liquidity, and willingness to invest in innovation despite short‑term pressure. The company has a legacy base of technical know‑how in pharmaceuticals and traditional medicine, and it has acquired AI platforms and capabilities that, if integrated well, could position it in attractive parts of the insurance and healthcare value chain. Recent improvements in gross margins and cost control show that management is actively adjusting the business rather than remaining static.
Key risks include the sharp and ongoing decline in revenue, persistent accounting and cash losses, and highly volatile cash flows. The strategic pivot is complex: combining pharma, healthcare, and insurance AI requires integrating very different businesses and managing regulatory, operational, and cultural challenges. Competitive intensity is high in both core areas – generic pharma and AI‑driven financial services – leaving limited room for missteps. Continued negative free cash flow could, over time, erode the current cash cushion and force the company to consider new financing or further restructuring if profitability does not recover.
The outlook for BGM is best described as uncertain and execution‑dependent. The balance sheet gives the company time to pursue its transformation, but the income statement and cash flows indicate that the traditional business alone is unlikely to restore past profitability. Future performance will hinge on stabilizing the legacy pharma segment, successfully scaling the AI insurance platforms, and translating rising R&D and capital investment into durable, cash‑generating revenue streams. Until there is clearer evidence of sustained top‑line growth and positive free cash flow from the new strategy, results are likely to remain volatile and sensitive to both market and execution factors.
CEO
Chen Xin
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-06-21 | Reverse | 1:5 |
ETFs Holding This Stock
Summary
Showing Top 3 of 4
Ratings Snapshot
Rating : B-